EGFR mutations are detected in some squamous cell carcinomas.21 However, when the rate of a positive test outcome is low, the health economics around testing are altered, and respondents in some countries cited cost as a reason patients were not tested. This evidence concerns the gene EGFR and squamous cell carcinoma.